日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Pharmacokinetic comparison of ezetimibe/rosuvastatin/telmisartan 10/20/80 mg fixed-dose combination versus coadministration of separate tablets in healthy participants

在健康受试者中，对依泽替米贝/瑞舒伐他汀/替米沙坦 10/20/80 mg 固定剂量复方制剂与分别服用各片剂的药代动力学进行比较

期刊:Naunyn-Schmiedebergs Archives of Pharmacology
影响因子:3.1
doi:10.1007/s00210-025-04903-4
Goh, Seoyoung; Huh, Ki Young; Lee, SeungHwan; Cho, Joo-Youn; Yu, Kyung-Sang
发表日期：2026
文献求助 收藏

Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects

在健康女性和肥胖受试者中多次口服给药后，vutiglabridin 的药代动力学、药效学和安全性研究

期刊:British Journal of Clinical Pharmacology
影响因子:3
doi:10.1002/bcp.70311
Lee, Sooyoun; Kim, Hyun Chul; Yoon, Young Ran; Jang, In-Jin; Yoo, Sang-Ku; Yu, Kyung-Sang
肥胖
代谢
发表日期：2026
文献求助 收藏

Exploratory Evaluation of Solanidine as an Endogenous Marker for CYP2D6-Mediated Drug-Drug-Gene Interactions of Venlafaxine in Koreans

探索性评价茄啶作为文拉法辛在韩国人体内CYP2D6介导的药物-药物-基因相互作用的内源性标志物

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.70564
Bae, Sungyeun; Lee, Ga-Yeong; Yang, Eunsol; Chae, Woori; Yu, Kyung-Sang; Cho, Joo-Youn; Kim, Anhye; Gu, Namyi; Lee, SeungHwan
发表日期：2026
文献求助 收藏

Population Pharmacokinetic Analysis of MIT-001, a Novel Ferroptosis Inhibitor, for Dose Optimization

MIT-001（一种新型铁死亡抑制剂）的群体药代动力学分析及其剂量优化

期刊:Journal of Clinical Pharmacology
影响因子:2.3
doi:10.1002/jcph.70189
Bae, Sungyeun; Kim, Eunwoo; Rhee, Su-Jin; Kim, Soonha; Yu, Kyung-Sang; Lee, SeungHwan
铁死亡
发表日期：2026
文献求助 收藏

Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Fenofibrate 20/145 mg and the Corresponding Individual Components

阿托伐他汀/非诺贝特20/145 mg固定剂量复方制剂与相应单药成分的药代动力学比较

期刊:Clinical Pharmacology in Drug Development
影响因子:1.8
doi:10.1002/cpdd.70043
Lee, Seungri; Khwarg, Juyoung; Bae, Sungyeun; Park, Dong-Min; Park, Heejung; Lee, SeungHwan; Yu, Kyung-Sang
发表日期：2026
文献求助 收藏

Exploratory comparative pharmacokinetic study of a fixed-dose combination of telmisartan/amlodipine/chlorthalidone: half-dose (20/2.5/6.25 mg) versus conventional dose (40/5/12.5 mg)

替米沙坦/氨氯地平/氯噻酮固定剂量组合的探索性比较药代动力学研究：半剂量（20/2.5/6.25 mg）与常规剂量（40/5/12.5 mg）

期刊:Translational and Clinical Pharmacology
影响因子:1.5
doi:10.12793/tcp.2026.34.e5
Chang, Kyungrin; Won, Heejae; Lee, Taewon; Kwon, Soonkeun; Lee, Seung Hwan; Cho, Joo-Youn; Yu, Kyung-Sang
发表日期：2026
文献求助 收藏

Correction: Pharmacokinetics of post-transplant cyclophosphamide and its associations with clinical outcomes in pediatric haploidentical hematopoietic stem cell transplantation

更正：移植后环磷酰胺的药代动力学及其与儿童单倍体相合造血干细胞移植临床结果的关系

期刊:Biomarker Research
影响因子:11.5
doi:10.1186/s40364-025-00781-3
Hong, Kyung Taek; Bae, Sungyeun; Sunwoo, Yoon; Lee, Juyeon; Park, Hyun Jin; Kim, Bo Kyung; Choi, Jung Yoon; Cho, Joo-Youn; Yu, Kyung-Sang; Oh, Jaeseong; Kang, Hyoung Jin
干细胞
发育与干细胞
细胞生物学
发表日期：2025
文献求助 收藏

Pharmacokinetics of post-transplant cyclophosphamide and its associations with clinical outcomes in pediatric haploidentical hematopoietic stem cell transplantation

儿童单倍体相合造血干细胞移植后环磷酰胺的药代动力学及其与临床结局的关系

期刊:Biomarker Research
影响因子:11.5
doi:10.1186/s40364-025-00749-3
Hong, Kyung Taek; Bae, Sungyeun; Sunwoo, Yoon; Lee, Juyeon; Park, Hyun Jin; Kim, Bo Kyung; Choi, Jung Yoon; Cho, Joo-Youn; Yu, Kyung-Sang; Oh, Jaeseong; Kang, Hyoung Jin
细胞生物学
发育与干细胞
干细胞
发表日期：2025
文献求助 收藏

Pharmacokinetic and Safety Profiles of MIT-001, a Novel Ferroptosis Inhibitor, After Subcutaneous Administration in Healthy Participants

新型铁死亡抑制剂MIT-001在健康受试者皮下注射后的药代动力学和安全性特征

期刊:Drug Design Development and Therapy
影响因子:5.1
doi:10.2147/DDDT.S541415
Lee, Sujong; Bae, Sungyeun; Yu, Kyung-Sang; Lee, SeungHwan
铁死亡
发表日期：2025
文献求助 收藏

Pharmacokinetics, Safety and Tolerability of Intravenous Lenzilumab, an Anti-GM-CSF Monoclonal Antibody Drug, in Healthy Korean Subjects

在健康韩国受试者中，静脉注射抗GM-CSF单克隆抗体药物Lenzilumab的药代动力学、安全性和耐受性研究

期刊:Drug Design Development and Therapy
影响因子:5.1
doi:10.2147/DDDT.S550126
Kang, Jaegu; Bae, Sungyeun; Yu, Kyung-Sang; Lee, SeungHwan
单克隆抗体
M-CSF
GM-CSF
发表日期：2025
文献求助 收藏